SUNC heads into its August 11 earnings call with analyst conviction building, options traders turning more cautious, and the stock nursing a modest two-day pullback from a strong monthly run.
The clearest signal this week comes from the Street. Barclays analyst Theresa Chen raised her price target to $80 this morning — the third lift in three months, from $63 in May to $73, then $78, and now $80 — while holding her Overweight rating. Mizuho initiated coverage just two weeks ago at Outperform with an $83 target, the most bullish on the board. The consensus sits at Buy with a mean target of $80.25, implying roughly 9% upside from Tuesday's close of $73.88. That's a tighter premium than a month ago, when the stock was trading nearly 8 points lower — the P/E multiple has compressed about 2.2 turns over the past 30 days to 10.4x, reflecting the stock's 7.8% monthly gain running ahead of earnings revisions. EV/EBITDA has similarly eased, down about 0.17 turns to 6.5x. The Street is constructive but the re-rating has already partly happened.
Options positioning has grown more defensive than usual. The put/call ratio has climbed to 0.65, well above its 20-day average of 0.36, putting it about one standard deviation above the norm — the highest sustained reading in roughly two months. Through most of June and early July the PCR was running below 0.1, so the shift over the past week is notable even if it doesn't yet read as extreme. With earnings scheduled for August 11, some of that hedging demand is likely pre-release positioning rather than a structural view.
The lending market tells a very different story — this is not a stock where short sellers are pressing hard. Borrow availability is exceptionally loose, with around 49x as many shares available to borrow as are currently borrowed. Short interest has been drifting lower, down about 2.4% on the week to roughly 1.52 million shares. Cost to borrow is a negligible 0.48%, down from a 30-day high near 0.76% in early July, meaning there is no friction for new short positions and no squeeze pressure worth monitoring. The ORTEX short score of 34.7 is low and has barely moved in two weeks, consistent with a name where bears are not materially engaged.
On the institutional side, the holder list is broad and reasonably active. FMR added over 729,000 shares as of May, lifting its stake to just under 10% of shares — the largest single holder. Harvest Fund Advisors built a sizeable new position through Q1, adding 1.74 million shares. Two Sigma and BCV Asset Management both appear to have initiated fresh positions in Q1, each starting from zero. Neuberger Berman added over 714,000 shares through June. The picture is one of accumulation across a range of institutions, not distribution. The insider data in the snapshot predates the 90-day window and should not be read as current signal.
The two prior earnings prints with reaction data offer a modest reference point: the May 18 result produced a 1.3% next-day gain but a 3.5% five-day reversal; the May 5 print saw an initial 1.6% dip followed by a 4.2% five-day recovery. Neither moved dramatically in the days immediately after. What to watch heading into August 11 is whether the string of analyst target increases — and the institutional accumulation behind them — holds up against whatever guidance accompanies the quarterly numbers, and whether options hedging demand intensifies further as the date approaches.
See the live data behind this article on ORTEX.
Open SUNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
